SYNBIOTIC COMBINATION OF PROBIOTIC AND HUMAN MILK OLIGOSACCHARIDES TO PROMOTE GROWTH OF BENEFICIAL MICROBIOTA
First Claim
Patent Images
1. A synthetic pediatric formula for promoting intestinal barrier integrity, the synthetic formula comprising a probiotic, a first oligosaccharide in a concentration of from about 1 mg/mL to about 4 mg/mL and selected from the group consisting of a galactooligosaccharide, a fructooligosaccharide, and combinations thereof;
- and a second oligosaccharide in a concentration of from about 0.05 mg/mL to about 0.5 mg/mL and selected from the group consisting of 2′
-fucosyllactose, 3′
-fucosyllactose, 3′
-sialyllactose, 6′
-sialyllactose, lacto-N-neotetraose, and combinations thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, and children for improving gastrointestinal function and tolerance, as well as the growth of beneficial microbiota. Suitable additional methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.
-
Citations
20 Claims
-
1. A synthetic pediatric formula for promoting intestinal barrier integrity, the synthetic formula comprising a probiotic, a first oligosaccharide in a concentration of from about 1 mg/mL to about 4 mg/mL and selected from the group consisting of a galactooligosaccharide, a fructooligosaccharide, and combinations thereof;
- and a second oligosaccharide in a concentration of from about 0.05 mg/mL to about 0.5 mg/mL and selected from the group consisting of 2′
-fucosyllactose, 3′
-fucosyllactose, 3′
-sialyllactose, 6′
-sialyllactose, lacto-N-neotetraose, and combinations thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
- and a second oligosaccharide in a concentration of from about 0.05 mg/mL to about 0.5 mg/mL and selected from the group consisting of 2′
-
9. A method of promoting the growth of beneficial microbiota in the gastrointestinal tract of an infant or toddler in need thereof, the method comprising administering to the infant or toddler a synthetic pediatric formula comprising a probiotic, a first oligosaccharide in a concentration of from about 1 mg/mL to about 4 mg/mL and selected from the group consisting of galactooligosaccharide, fructooligosaccharide, and combinations thereof;
- and a second oligosaccharide in a concentration of from about 0.05 mg/mL to about 0.5 mg/mL and selected from the group consisting of 2′
-fucosyllactose, 3′
-fucosyllactose, 3′
-sialyllactose, 6′
-sialyllactose, lacto-N-neotetraose, and combinations thereof. - View Dependent Claims (10, 11, 12, 13, 14, 15, 16, 17)
- and a second oligosaccharide in a concentration of from about 0.05 mg/mL to about 0.5 mg/mL and selected from the group consisting of 2′
-
18. A method of stimulating enteric nerve cells in the gastrointestinal tract of an infant or toddler in need thereof, the method comprising administering to the infant or toddler a synthetic pediatric formula comprising a probiotic, a first oligosaccharide in a concentration of from about 1 mg/mL to about 4 mg/mL and selected from the group consisting of galactooligosaccharide, fructooligosaccharide, and combinations thereof;
- and a second oligosaccharide in a concentration of from about 0.05 mg/mL to about 0.05 mg/mL and selected from the group consisting of 2′
-fucosyllactose, 3′
-fucosyllactose, 3′
-sialyllactose, 6′
-sialyllactose, lacto-N-neotetraose, and combinations thereof. - View Dependent Claims (19, 20)
- and a second oligosaccharide in a concentration of from about 0.05 mg/mL to about 0.05 mg/mL and selected from the group consisting of 2′
Specification